Active Ingredient History
Clarithromycin is an antibacterial drug which is used either in combination with lansoprazole and amoxicillin (Prevpac), in combination with omeprazole and amoxicillin (Omeclamox) or alone (Biaxin) for the treatment of broad range of infections. The drug exerts its action by binding to 23s rRNA (with nucleotides in domains II and V). The binding leads to the protein synthesis inhibition and the cell death. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Bronchitis, Chronic (approved 1991)
Helicobacter Infections (approved 1991)
Maxillary Sinusitis (approved 1991)
Mycobacterium Infections (approved 1991)
Otitis Media (approved 1991)
Pharyngitis (approved 1991)
Pneumonia, Bacterial (approved 1991)
Skin Diseases, Infectious (approved 1991)
Tonsillitis (approved 1991)
Aggressive Periodontitis (Phase 2/Phase 3)
Anemia, Iron-Deficiency (Phase 4)
Anovulation (Phase 1)
Appendiceal Neoplasms (Phase 2)
Appendicitis (Phase 2)
Asthma (Phase 4)
Bacterial Infections (Phase 4)
Biomarkers (Phase 3)
Bismuth (Phase 4)
Borrelia Infections (Phase 4)
Bronchiectasis (Phase 3)
Bronchiolitis (Phase 3)
Bronchiolitis Obliterans (Phase 3)
Bronchitis (Phase 3)
Bronchitis, Chronic (Phase 4)
Bronchopulmonary Dysplasia (Phase 3)
Buruli Ulcer (Phase 2/Phase 3)
Cachexia (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Cardiovascular Diseases (Phase 3)
Community-Acquired Infections (Phase 4)
Coronavirus Infections (Phase 2)
COVID-19 (Phase 4)
Crohn Disease (Phase 4)
Cytochrome P-450 CYP2C19 (Phase 4)
Cytochrome P-450 CYP2D6 (Phase 1)
Cytochrome P-450 CYP3A (Phase 1)
Depressive Disorder, Major (Phase 1)
Disease Eradication (Phase 4)
Disorders of Excessive Somnolence (Phase 2)
Drug Interactions (Phase 1)
Drug Resistance, Bacterial (Phase 3)
Duodenal Ulcer (Phase 3)
Dyspepsia (Phase 4)
Endoscopy (Phase 3)
Extensively Drug-Resistant Tuberculosis (Phase 4)
Family (Phase 3)
Gastritis (Phase 4)
Gastritis, Atrophic (Phase 4)
Gastroesophageal Reflux (Phase 4)
Healthy Volunteers (Phase 2/Phase 3)
Heart Diseases (Phase 3)
Helicobacter (Phase 4)
Helicobacter Infections (Phase 4)
Helicobacter pylori (Phase 4)
HIV (Phase 3)
HIV Infections (Phase 3)
Idiopathic Hypersomnia (Phase 2)
Infant, Premature (Phase 3)
Infant, Very Low Birth Weight (Phase 2)
Infections (Phase 4)
Inflammation (Phase 3)
Influenza A virus (Phase 2)
Influenza, Human (Phase 4)
Intestinal Neoplasms (Phase 4)
Intestinal Polyps (Phase 4)
Leukemia, B-Cell (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Lung Diseases (Phase 4)
Lung Neoplasms (Phase 2)
Lyme Disease (Phase 4)
Lymphoma (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Non-Hodgkin (Phase 3)
Mortality (Phase 3)
Motor Activity (Phase 3)
Multiple Myeloma (Phase 3)
Multiple Organ Failure (Phase 3)
Multiple Sclerosis, Relapsing-Remitting (Phase 2)
Mycobacterium avium Complex (Phase 4)
Mycobacterium ulcerans (Phase 2/Phase 3)
Mycoplasma (Phase 2)
Mycoses (Phase 1)
Narcolepsy (Phase 2)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 2)
Neoplasms, Second Primary (Phase 3)
Nontuberculous Mycobacteria (Phase 4)
Otitis Media (Phase 3)
Oxidative Stress (Phase 1)
Parkinson Disease (Phase 3)
Peptic Ulcer (Phase 4)
Peptic Ulcer Hemorrhage (Phase 3)
Periodontitis (Phase 4)
Pharmacokinetics (Phase 1)
Pharyngitis (Phase 3)
Pneumonia ()
Pneumonia, Bacterial (Phase 4)
Pneumonia, Ventilator-Associated (Phase 4)
Pregnancy Complications (Phase 4)
Prostatic Neoplasms (Phase 1)
Pseudomyxoma Peritonei (Phase 2)
Purpura (Phase 4)
Purpura, Thrombocytopenic, Idiopathic (Phase 4)
Respiratory Distress Syndrome (Phase 3)
Respiratory Tract Infections (Phase 4)
Sepsis (Phase 4)
Shock, Septic (Phase 3)
Sinusitis (Phase 3)
Sprains and Strains (Phase 3)
Stomach Diseases (Phase 4)
Stomach Neoplasms (Phase 4)
Stomach Ulcer (Phase 3)
Systemic Inflammatory Response Syndrome (Phase 3)
Therapeutics (Phase 4)
Tonsillitis (Phase 3)
Toxoplasmosis, Cerebral (Phase 2)
Tuberculosis, Multidrug-Resistant (Phase 4)
Ulcer (Phase 4)
Venous Thromboembolism (Phase 1)
Virus Diseases (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
